Innate Pharma SA ADR IPHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
-
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
-
Innate Pharma Reports First Half 2026 Business Update and Financial Results
-
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
-
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
-
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
Innate Pharma Announces Conference Call and Webcast
-
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.48–1.52
- 52-Week Range
- $1.17–2.71
- Bid/Ask
- $1.35 / $1.79
- Shares Outstanding
- 111.70M
- Market Cap
- $167.55M
- Volume/Avg
- 11,924 / 154,597
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 163
- Website
- https://www.innate-pharma.com
Valuation
|
Metric
|
IPHA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 28.28 |
Price/Cash Flow | — |
Price/Earnings
IPHA
Financial Strength
|
Metric
|
IPHA
|
|---|---|
Quick Ratio | 0.47 |
Current Ratio | 0.60 |
Interest Coverage | −125.67 |
Quick Ratio
IPHA
Profitability
|
Metric
|
IPHA
|
|---|---|
Return on Assets (Normalized) | −70.64% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,065.63% |
Return on Assets
IPHA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>^tr^G# | LOCK|x!k@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|XY##>dr | LOCK|C%qX^ | $83B | |||
| Moderna Inc
MRNA
| LOCK|p@#!R&$ | LOCK|Kyf | $80B | |||
| argenx SE ADR
ARGX
| LOCK|%<d#$#R | LOCK|XMD | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@#Xm%> | LOCK|XB$ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fwL>zp | LOCK|@Sb#k | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$YmQkLX$ | LOCK|?jR? | $28B | |||
| Incyte Corp
INCY
| LOCK|Jh^!$Z^ | LOCK|nr | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|><t#Cy | LOCK|%! | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|l$Tg<$N | LOCK|Y>! | $14B |
United States